Avadel Pharmaceuticals Selects TCG for Head of Total Rewards Search

ST. LOUIS, MISSOURIAvadel Pharmaceuticals, a dynamic biopharmaceutical company driven by a mission to transform medicines and improve lives, has selected The Christopher Group to lead their Head of Total Rewards search. Managing Partner, Ayla Maloney and Recruiting Director, Carrie Longmire are leading the pivotal HR search.

“Angela Woods is an incredible, values-driven HR leader that is in the midst of building a world-class People function.  This head of Total Rewards will get to collaborate with her and the other business executives to build a competitive, modern and innovative rewards function.  Avadel is a curious, relentless, and fast growing pharmaceutical business that will make a positive impact on so many.  It’s an honor to partner with them.” shared Ayla, Managing Partner at The Christopher Group.

The Head of Total Rewards is a strategic, hands-on leader reporting to the Head of HR, collaborating with executive leadership to design and align rewards initiatives with Avadel’s core values and business objectives. The Head of Total Rewards will have a significant impact on shaping the future of Avadel’s workforce by developing and overseeing comprehensive compensation and benefits strategies that support the mission.  They will be responsible for designing competitive salary structures, managing incentive and equity programs, and ensuring all rewards strategies foster inclusivity, collaboration, and innovation. The Head of Total Rewards will also be a trusted advisor on compensation matters, providing insights and recommendations based on market trends and industry best practices. In addition to compensation, they will oversee Avadel’s benefits programs, including health plans, retirement, and wellness initiatives. Their leadership will ensure these offerings meet the diverse needs of Avadel’s employees, utilizing data and analytics to assess program effectiveness, while reflecting their commitment to stewardship and well-being.  

To learn more about this opportunity and/or The Christopher Group please contact Carrie Longmire at carrie@tcgco.com.

About Avadel Pharmaceuticals

Avadel Pharmaceuticals is a dynamic biopharmaceutical company driven by a mission to transform medicines and improve lives. They focus on innovative solutions that tackle the challenges patients face with current treatment options. One of the company’s key advancements is in the area of oxybate therapy, which is a widely used treatment for excessive daytime sleepiness (EDS) and cataplexy in individuals with narcolepsy. While traditional oxybate products require two nightly doses—one at bedtime and another in the middle of the night—Avadel has revolutionized this with their new therapy, LUMRYZ. 

LUMRYZ, which received FDA approval on May 1, 2023, offers a once-nightly dose that eliminates the need for patients to wake up during the night for a second dose. This major improvement has earned LUMRYZ seven years of Orphan Drug Exclusivity from the FDA, and it is recognized as clinically superior to the previously available therapies. 

What sets Avadel apart is its dedication to making a positive impact—not just for patients but also for their community and one another. Employees live the Avadel Values in everything they do, which is what makes working at Avadel a special experience.  

About The Christopher Group

Through its award-winning, customized HR solutions, The Christopher Group (TCG) delivers critical human capital solutions in the area of executive HR search, interim HR leaders, fractional CHROs, and HR advisory and consulting. Since 1998, TCG has served clients across all industries, locations, company sizes, and verticals. Staffed by former HR professionals and highly trained search practitioners who have sat in the job, TCG has been named one of the Fastest-Growing, Best Non-Profit, Diversity, Private Equity, and Top 50 Executive Recruiting Firms by Hunt Scanlon as well as Forbes’ 2019, 2020, 2021 & 2022 list of America’s Best Executive Recruiting Firms.